drugset / Trial / NCT05067348
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.
Timeline
- Start
- 2022-07-21
- Primary completion
- 2025-12-31
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | — | Intravenous |